Immunogenicity and Safety of a Third COVID-19 BNT162b2 mRNA Vaccine Dose in 5- to 11-Year Olds

C4591007 Clinical Trial Group

Research output: Contribution to journalArticlepeer-review

2 Scopus citations

Abstract

In this ongoing study, substantially increased ancestral SARSCoV-2 neutralizing responses were observed 1 month after a third 10-µg BNT162b2 dose given to 5 to 11-year olds versus neutralizing responses post-dose 2. After dose 3, increased neutralizing responses against Omicron BA.1 and BA.4/BA.5 strains were also observed. The safety/tolerability profile was acceptable.

Original languageEnglish (US)
Pages (from-to)234-238
Number of pages5
JournalJournal of the Pediatric Infectious Diseases Society
Volume12
Issue number4
DOIs
StatePublished - Apr 1 2023

Keywords

  • BNT162b2 vaccine
  • COVID-19
  • booster
  • children
  • immunogenicity
  • safety

ASJC Scopus subject areas

  • General Medicine

Fingerprint

Dive into the research topics of 'Immunogenicity and Safety of a Third COVID-19 BNT162b2 mRNA Vaccine Dose in 5- to 11-Year Olds'. Together they form a unique fingerprint.

Cite this